MB-CAR-T19-22
/ Miltenyi Biotec
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 04, 2025
CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies
(ASH 2025)
- "Lymphodepletion was performed using fludarabine (25mg/m²/day, days –5 to –3) and cyclophosphamide (1000 mg/m², day –3). The investigational CD19/CD22-targeted CAR-T cell product demonstrated encouragingefficacy with a manageable safety profile in heavily pretreated adult patients with relapsed/refractory B-cell malignancies, including post-transplant settings. Dual targeting may offer therapeutic advantages inovercoming antigen escape and achieving durable remissions. Based on promising results, a Phase Idose-finding and efficacy study of a third-generation CAR-T cell product (MB-CART19.22), is planned inadult and pediatric patients with relapsed or refractory B-cell malignancies."
CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Rare Diseases • Richter's Syndrome • Septic Shock • Squamous Cell Carcinoma • CD22
February 22, 2023
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
(clinicaltrials.gov)
- P1/2 | N=50 | Active, not recruiting | Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Mar 2027 | Trial primary completion date: Dec 2022 ➔ Mar 2022
Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • CD22
1 to 2
Of
2
Go to page
1